NDLI: Patients' acceptance of the deltoid application of risperidone long-acting injection.

Please wait, while we are loading the content...

Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.

On assessing potential efficacy for vortioxetine in generalized anxiety disorder.

Neuropsychopharmacology across brain diseases.

Year: 2012 Volume: 22 Issue: 11

Year: 2012 Volume: 22 Issue: 10

Year: 2012 Volume: 22 Issue: 9

Year: 2012 Volume: 22 Issue: 8

Year: 2012 Volume: 22 Issue: 7

Year: 2012 Volume: 22 Issue: 6

Year: 2012 Volume: 22 Issue: 5

Year: 2012 Volume: 22 Issue: 4

Year: 2012 Volume: 22 Issue: 3

Year: 2012 Volume: 22 Issue: 2

Year: 2012 Volume: 22 Issue: 1

Year: 2011 Volume: 21

Year: 2010 Volume: 20

Year: 2009 Volume: 19

Year: 2008 Volume: 18

Year: 2007 Volume: 17

Year: 2006 Volume: 16

Patients' acceptance of the deltoid application of risperidone long-acting injection.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Heres, Stephan Frobose, Teresa Hamann, Johannes Leucht, Stefan Maino, Katja Reichhart, Tatjana Stiegler, Michaela Kissling, Werner
Description	Country affiliation: Germany Author Affiliation: Heres S ( Klinik und Poliklinik fuer Psychiatrie und Psychotherapie, der Technischen Universitaet Muenchen, am Klinikum rechts der Isar, Muenchen, Germany. s.heres@lrz.tum.de)
Abstract	OBJECTIVE: Recently risperidone long-acting injection (RLAI) was approved for alternative injection into the deltoid muscle in addition to the already established injection into the gluteal muscle. For the first time two different injection locations of a long-acting antipsychotic injection can be offered to patients. Their actual acceptance is of key interest. EXPERIMENTAL PROCEDURES: We surveyed 60 patients stabilized on gluteal RLAI therapy in our depot outpatient clinic. Participants were offered the possibility of switching to the alternative deltoid injection in a standardized manner. Prior to switching patients scored the extent of perceived pain and experienced level of shame through the present gluteal injection therapy on a 7-point-scale. Patients choosing to switch were followed up after three months and asked to report on their individual experience. RESULTS: Switching to the deltoid application was chosen by 34 out of 60 patients. Three months later 15 patients were still receiving deltoid injections. The main reason for their staying with the deltoid injection was improved practicability as reported by these patients and 13 out of 15 patients clearly preferred the new location over the gluteal application. The main reason for returning to the gluteal injection was the pain experienced through the injection in the deltoid. Patients' initial decision whether to switch was not correlated with either perceived pain or the experienced level of shame through the preceding gluteal injections. CONCLUSIONS: The application of RLAI in the deltoid muscle is viewed as an alternative to the injection in the gluteal muscle by a considerable number of patients. Nevertheless, some patients experience increased injection pain through this application location while others perceive the switch as beneficial in terms of practicability. Therefore offering both injection locations with their respective pros and cons should become standard in the RLAI treatment offered.
File Format	HTM / HTML
ISSN	0924977X
Issue Number	12
Volume Number	22
e-ISSN	18737862
Journal	European Neuropsychopharmacology
Language	English
Publisher	Elsevier
Publisher Date	2012-12-01
Publisher Place	Netherlands
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Psychopharmacology Deltoid Muscle Drug Effects Patient Satisfaction Risperidone Administration & Dosage Adult Delayed-action Preparations Pharmacology Physiology Female Humans Injections, Intramuscular Male Middle Aged Treatment Outcome Journal Article Randomized Controlled Trial Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Neurology Biological Psychiatry Neurology (clinical) Pharmacology Pharmacology (medical) Psychiatry and Mental Health

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.

Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients.

The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.

Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

Long-acting risperidone: a review of its role in the treatment of bipolar disorder.

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.

Patients' acceptance of the deltoid application of risperidone long-acting injection.

Similar Documents

Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.

Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients.

The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.

Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

Long-acting risperidone: a review of its role in the treatment of bipolar disorder.

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.

Patients' acceptance of the deltoid application of risperidone long-acting injection.